Generalised tonic-clonic seizure – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Generalised tonic-clonic seizure – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures https://clinicaltrials.eu/trial/study-of-prax-628-to-evaluate-safety-and-effectiveness-in-adults-with-epilepsy-who-have-focal-seizures-or-generalized-tonic-clonic-seizures/ Thu, 30 Apr 2026 13:08:08 +0000 https://clinicaltrials.eu/trial/study-of-prax-628-to-evaluate-safety-and-effectiveness-in-adults-with-epilepsy-who-have-focal-seizures-or-generalized-tonic-clonic-seizures/ This clinical trial studies the use of vormatrigine (also known as PRAX-628) in adults who have epilepsy with either focal onset seizures or primary generalized tonic-clonic seizures. These types of seizures are different forms of epilepsy where electrical disturbances in the brain cause sudden, uncontrolled movements or changes in behavior.

The study aims to determine how safe and well-tolerated vormatrigine is when given to patients who have previously received this medication in other studies or through special access programs. The medication comes in the form of capsules that are taken by mouth. The treatment period may last up to 24 months.

During the study, doctors will monitor patients’ health through various tests and check how well the medication is working to control seizures. They will pay special attention to any side effects that might occur during treatment and measure the amount of medication in patients’ blood. The study will also track changes in the severity of the condition as observed by both doctors and patients.

]]> Study on PRAX-628 for Adults with Focal Onset or Generalized Tonic-Clonic Seizures https://clinicaltrials.eu/trial/study-on-prax-628-for-adults-with-focal-onset-or-generalized-tonic-clonic-seizures/ Wed, 29 Apr 2026 15:03:01 +0000 https://clinicaltrials.eu/trial/study-on-prax-628-for-adults-with-focal-onset-or-generalized-tonic-clonic-seizures/ This clinical trial is focused on studying the effects of a new treatment called PRAX-628 for adults who experience certain types of seizures. The seizures being studied are known as focal onset seizures and primary generalized tonic-clonic seizures. These are types of epilepsy where the person may experience sudden bursts of electrical activity in the brain, leading to convulsions or other symptoms.

The purpose of the study is to evaluate how effective PRAX-628 is in reducing the frequency of these seizures. Participants in the study will take PRAX-628 in the form of a capsule, which is taken orally. The study will last for a period of up to eight weeks, during which participants will continue their usual anti-seizure medications while adding PRAX-628 to their treatment plan. The study will monitor changes in seizure frequency and any side effects experienced by participants.

Throughout the study, participants will be asked to keep a diary of their seizures and any changes they notice. The study aims to see if PRAX-628 can help reduce the number of seizures and improve the overall quality of life for those affected by these types of epilepsy. The results will help determine the safety and effectiveness of PRAX-628 as a potential new treatment option for people with these seizure disorders.

]]> Study on the Long-term Safety of Cenobamate for Patients with Primary Generalized Tonic-Clonic Seizures https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-cenobamate-for-patients-with-primary-generalized-tonic-clonic-seizures/ Wed, 29 Apr 2026 14:29:32 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-cenobamate-for-patients-with-primary-generalized-tonic-clonic-seizures/ This clinical trial is focused on studying the long-term safety of a treatment for people with Primary Generalized Tonic-Clonic Seizures, a type of seizure that affects the whole brain and causes convulsions. The treatment being tested is called Cenobamate, which is used as an additional therapy to help manage these seizures. Cenobamate is available in different forms, including tablets and oral suspension, and is also known by the code name YKP3089.

The purpose of this study is to evaluate how safe and tolerable Cenobamate is for individuals with this type of seizure. Participants in the study will receive either Cenobamate or a placebo, which looks like the real medication but does not contain the active substance. The study will monitor participants over a period to observe any side effects or changes in their health. This will help researchers understand the long-term effects of using Cenobamate as a treatment.

Throughout the study, participants will take the medication by mouth, either as a tablet or an oral suspension. The study will last for a set period, during which participants will have regular check-ups to assess their health and any potential side effects. The goal is to ensure that Cenobamate is a safe option for managing Primary Generalized Tonic-Clonic Seizures over an extended period.

]]> Study on the Effectiveness and Safety of Cenobamate for Patients Aged 12 and Older with Primary Generalized Tonic-Clonic Seizures https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cenobamate-for-patients-aged-12-and-older-with-primary-generalized-tonic-clonic-seizures/ Wed, 29 Apr 2026 14:27:49 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cenobamate-for-patients-aged-12-and-older-with-primary-generalized-tonic-clonic-seizures/ This clinical trial is focused on studying the effects of a medication called cenobamate on individuals experiencing Primary Generalized Tonic-Clonic Seizures. These seizures are a type of epilepsy characterized by sudden and severe muscle contractions and loss of consciousness. The study aims to evaluate how effective and safe cenobamate is when used alongside other treatments for these seizures. Participants in the study will receive either cenobamate or a placebo, which looks like the medication but does not contain the active ingredient.

The trial involves taking cenobamate in different forms, such as tablets or an oral suspension, which is a liquid form of the medication. The study will last for several months, during which participants will be monitored to see how their seizures respond to the treatment. The goal is to determine if cenobamate can reduce the frequency of seizures and improve the quality of life for those affected by this condition.

Throughout the study, participants will have regular check-ups to assess their health and any changes in their seizure patterns. The information gathered will help researchers understand the potential benefits and any side effects of using cenobamate as an additional therapy for managing Primary Generalized Tonic-Clonic Seizures. This research is important for developing better treatment options for people living with epilepsy.

]]> Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures https://clinicaltrials.eu/trial/study-on-the-long-term-safety-and-tolerability-of-azetukalner-for-patients-with-epilepsy-including-focal-onset-and-primary-generalized-tonic-clonic-seizures/ Wed, 29 Apr 2026 14:26:42 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-safety-and-tolerability-of-azetukalner-for-patients-with-epilepsy-including-focal-onset-and-primary-generalized-tonic-clonic-seizures/ This clinical trial is focused on studying the effects of a medication called XEN1101 in people diagnosed with epilepsy. Specifically, it looks at two types of seizures: focal-onset seizures, which start in one area of the brain, and primary generalized tonic-clonic seizures, which affect the whole brain. The medication being tested, XEN1101, is taken in the form of a capsule and is designed to help manage these types of seizures.

The purpose of this study is to understand how safe and tolerable long-term use of XEN1101 is for people with epilepsy. Participants in the study will take the medication over a period of time, and researchers will monitor them to see how they respond to the treatment. This includes looking at any side effects they might experience and how their seizure frequency changes. The study will also assess the overall impact on participants’ quality of life and any changes in their health over time.

Throughout the study, participants will be asked to take the medication regularly and attend scheduled check-ups. These check-ups will help researchers gather important information about the medication’s effects. The study aims to provide valuable insights into the long-term use of XEN1101 for managing epilepsy, which could help improve treatment options for people living with this condition.

]]> Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures https://clinicaltrials.eu/trial/study-on-the-effects-of-xen1101-and-placebo-for-patients-with-primary-generalized-tonic-clonic-seizures/ Wed, 29 Apr 2026 14:24:08 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-xen1101-and-placebo-for-patients-with-primary-generalized-tonic-clonic-seizures/ This clinical trial is focused on studying the effects of a medication called XEN1101 on individuals who experience Primary Generalized Tonic-Clonic Seizures. These seizures are a type of epilepsy that involves sudden and severe muscle contractions and loss of consciousness. The study aims to evaluate how well XEN1101 can reduce the frequency of these seizures when used alongside other treatments.

Participants in the study will be randomly assigned to receive either XEN1101 or a placebo, which is a capsule that looks like the medication but does not contain the active substance. The medication is taken orally in the form of a capsule. The study will last for a period of 12 weeks, during which the safety and effectiveness of XEN1101 will be closely monitored. The goal is to see if the medication can help reduce the number of seizures experienced by participants.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased. The trial will also assess how well participants tolerate the medication and any potential side effects. The ultimate aim is to determine if XEN1101 can be a beneficial addition to existing treatments for those suffering from Primary Generalized Tonic-Clonic Seizures.

]]>